<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446834</url>
  </required_header>
  <id_info>
    <org_study_id>[2015]018K</org_study_id>
    <nct_id>NCT02446834</nct_id>
  </id_info>
  <brief_title>Research of Intensive Lifestyle Intervention for PCOS Patients With IGT</brief_title>
  <official_title>Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor
      Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their
      metabolic and reproductive abnormalities treatment; clear the treatment effect and mechanism
      of intensive lifestyle intervention to PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a non randomized control study to compare the efficacy between intensive
      lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS
      patients with early onset diabetes in their metabolic and reproductive abnormalities
      treatment We planed to enroll 48 patients.Overweight and obese PCOS patients with newly
      diagnosed IGT; PCOS diagnosis based on 1990 NIH criteria. Overweight / obesity diagnostic
      criteria according to WHO-WPR. IGT diagnostic criteria according to 1998 WHO diagnostic
      criteria. Except for serious complications (cardiovascular events and recent significant
      kidney or lung disease within 3 months), and had high blood pressure (&gt;160/100mmHg), blood
      sugar and high blood lipids (glycated hemoglobin&gt; 11%, triglycerides &gt;600 mg/dl).

      Then we devided the 48 patients into 4 groups: intensive lifestyle intervention group, GLP-1
      group, metformin group and acarbose group, and each group 12 samples. Each group use specific
      treatment(showed as the group name) 3 months. Before and after the intervention, the blood
      samples would be collected to Glucose, Insulin, GLP-1, Glucagon, sex hormones, Blood
      chemistry for liver and kidney function ect, as well as the image examinations.

      We will compare the data of each patient, finally identify the treatment effect and mechanism
      of intensive lifestyle intervention to PCOS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes of Islet β-cell functions from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Insulin and blood glucose levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>GLP-1, glucagon，GIP, PYY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-abdominal fat distribution</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex Hormone</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>intensive lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months intensive lifestyle intervention, including low GI diet and exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 Receptor Agonists</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months GLP-1 Receptor Agonists treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months metformin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months acarbose treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>intensive lifestyle intervention</intervention_name>
    <description>3 months low GI diet and exercise</description>
    <arm_group_label>intensive lifestyle intervention</arm_group_label>
    <other_name>group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 Receptor Agonists</intervention_name>
    <description>Use GLP-1 Receptor Agonists 3 months to treat PCOS</description>
    <arm_group_label>GLP-1 Receptor Agonists</arm_group_label>
    <other_name>group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Use metformin 3 months to treat PCOS</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>group 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Use acarbose 3 months to treat PCOS</description>
    <arm_group_label>acarbose</arm_group_label>
    <other_name>group 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight and obese PCOS patients with newly diagnosed IGT; PCOS diagnosis based on
             1990 NIH criteria. Overweight / obesity diagnostic criteria according to WHO-WPR. IGT
             diagnostic criteria according to 1998 WHO diagnostic criteria.

        Exclusion Criteria:

          -  Except for serious complications (cardiovascular events and recent significant kidney
             or lung disease within 3 months), and had high blood pressure (&gt;160/100mmHg), blood
             sugar and high blood lipids (glycated hemoglobin&gt; 11%, triglycerides &gt;600 mg/dl).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Tao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital Department of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Tao, MD</last_name>
    <phone>+86-13817701776</phone>
    <email>taotaozhen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendi Xu, MD</last_name>
    <phone>+86-13564671899</phone>
    <email>cindy_525@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital Department of Endocrinology and Metabolism</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Liu, MD</last_name>
      <phone>+86-18918358342</phone>
      <email>sue_liuwei@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Ma, MD</last_name>
      <phone>+86-15800983436</phone>
      <email>cherry1996@live.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>intensive lifestyle intervention</keyword>
  <keyword>IGT</keyword>
  <keyword>drugs treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

